ecrin-mdr-crcClinical2003Colorectal CancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2010121United States8ECRIN MDRCompletedfalseA Study of ABT-751 in Patients With Colorectal CancerThe purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.2003-08-152010121NCT00073138